December 21, 2023 Flexible approaches to eCOA administration in clinical trials: The site perspective The Critical Path Institute convened the Support Flexible Approaches to PRO Data Collection project as part of the eCOA: Gettin
C-Path Partners with Unite4TB to Create a New Dawn in the Fight Against Tuberculosis C-Path is proud to be part of UNITE4TB, a public-private partnership funded by the Innovative Medicines Initiative and part of the
ASN PKDOC Poster — November 2023: Despite the regulatory advances in ADPKD including the qualification of total kidney volume (TKV) as a prognostic enrichment bioma
eCOA Consortium Announces Publication of an Open Access Article C-Path’s eCOA Consortium is pleased to announce the publication of an open access article in Value in Health titled “Best Prac
Critical Path for Parkinson’s Welcomes New Co-chairs Pagano, Gaetano Critical Path for Parkinson’s mission is to serve as a leading international consortium convening diverse stakeholders to
October 3, 2023 C-Path Rare and Orphan Disease Conference Highlights Unprecedented Collaborations and Breakthroughs in Rare Disease Research TUCSON, Ariz., October 3, 2023 — The Critical Path Institute (C-Path) held its highly anticipated Rare and Orphan Disease Confer
The CPP Consortium Welcomes Biohaven as its Newest Member The Critical Path for Parkinson’s Consortium is excited to welcome Biohaven as its newest member. Biohaven is a biopha
C-Path’s Romero Appears on The BioCentury Show Klaus Romero, Chief Science Officer at Critical Path Institute, occupies a rare role in the industry, as the top scientist in an o
C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium AcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an